Opinion

Video

Future Perspectives on HER2 ADCs in Gynecological Cancer

Author(s):

Ritu Salani, MD,Martin Dietrich, MD, PhD

Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.

Dr. Ritu Salani and Dr. Martin Dietrich discuss the future of HER2-directed antibody-drug conjugates (ADCs) in gynecologic malignancies and the importance of standardizing testing across cancer sites.

Dr. Salani expresses optimism about the role of ADCs in gynecologic cancers but cautions against grouping all gynecologic malignancies together due to their distinct behaviors and existing standard therapies. She emphasizes the need to carefully consider where ADCs fit into treatment algorithms, such as their potential use as a post-chemotherapy strategy in endometrial cancer or as a second-line option in cervical and ovarian cancers.

Dr. Salani highlights the compelling data in carcinosarcoma, a challenging histology to treat, and suggests that further studies are warranted. She anticipates that ADCs will likely move to the second-line setting across the board, with studies exploring earlier use in HER2-positive patients. Standardizing HER2 testing is crucial to optimize patient selection and ensure appropriate use of these drugs.

Dr. Dietrich echoes Dr. Salani's optimism and notes the surprising prevalence of HER2 positivity across epithelial malignancies when accounting for non-amplified cases. He emphasizes the importance of recognizing ADCs as a pan-tumor treatment option while still maintaining subspecialty expertise.

Both doctors agree that the efficacy and safety of ADCs will guide treatment decisions when multiple biomarkers are present. The inclusion of ADCs in NCCN guidelines for various cancers provides a strong incentive for HER2 testing. They conclude by highlighting the value of cross-disciplinary discussions and the potential for further advancements in HER2-directed therapies.

Summary generated by Claude AI.

Related Videos
Kathleen N. Moore, MD, MS
Matthew Powell, MD
Alberto Montero, MD, MBA, CPHQ
Kathleen N. Moore, MD, MS
Matthew Powell, MD
Laura J. Chambers, DO
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Maurie Markman, MD
Salman R. Punekar, MD
Related Content
Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, Diana Hyland Chair for Breast Cancer, University Hospitals Seidman Cancer Center
November 20th 2024

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Gynecologic Oncology
November 14th 2024

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute
November 5th 2024

Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27